Stock Analysis on Net

This company has been moved to the archive! The financial data has not been updated since February 27, 2025.

Analysis of Long-term (Investment) Activity Ratios 
Quarterly Data

Microsoft Excel

Long-term Activity Ratios (Summary)

Cigna Group, long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net fixed asset turnover 67.36 64.44 61.03 56.79 52.53 48.12 47.67 47.44 47.53 47.84 48.61 47.95 46.73 41.42 40.56 39.29 37.85
Total asset turnover 1.58 1.47 1.39 1.34 1.27 1.26 1.23 1.23 1.25 1.24 1.17 1.15 1.11 1.09 1.07 1.06 1.02
Equity turnover 6.00 5.50 5.24 4.97 4.20 4.13 4.07 4.09 4.00 3.98 3.88 3.81 3.66 3.56 3.40 3.36 3.16

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


Net fixed asset turnover
The net fixed asset turnover ratio demonstrates a consistent upward trend over the observed periods. Starting from 37.85 in March 2020, it gradually increased to 41.42 by December 2020. From 2021 onwards, the ratio continued to rise steadily, reaching 47.53 in March 2023 and further increasing to 67.36 by December 2024. This upward trajectory indicates improving efficiency in the use of fixed assets to generate sales.
Total asset turnover
The total asset turnover ratio shows a progressive increase throughout the timeline. From a level of 1.02 in March 2020, the ratio edged upward each quarter, climbing to 1.24 by December 2021. The upward momentum persisted through subsequent years, with the ratio rising to 1.25 in March 2023 and ultimately reaching 1.58 by December 2024. This trend suggests enhanced overall asset utilization to produce revenue over time.
Equity turnover
The equity turnover ratio has consistently increased across the periods observed. Starting at 3.16 in March 2020, it grew steadily to 3.56 by December 2020. Following this, the ratio continued to strengthen progressively, reaching 4.00 in March 2023 and then accelerating further to 6.00 by the end of 2024. This pattern reflects an improved ability to generate sales from shareholders' equity, indicating increased operational efficiency and potentially higher financial leverage.

Net Fixed Asset Turnover

Cigna Group, net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Revenues from external customers 65,372 63,609 60,202 56,965 50,824 48,727 48,308 46,240 45,539 45,076 45,155 43,591 45,308 43,820 42,821 40,580 41,341 40,658 39,042 38,116
Property and equipment 3,654 3,594 3,551 3,607 3,695 3,924 3,884 3,837 3,774 3,744 3,659 3,661 3,692 4,070 4,078 4,114 4,205 4,203 4,255 4,317
Long-term Activity Ratio
Net fixed asset turnover1 67.36 64.44 61.03 56.79 52.53 48.12 47.67 47.44 47.53 47.84 48.61 47.95 46.73 41.42 40.56 39.29 37.85
Benchmarks
Net Fixed Asset Turnover, Competitors2
Abbott Laboratories 3.94 3.88 3.98 3.99 3.95 4.18 4.26 4.47 4.76 5.18 5.17 5.00 4.81 4.79 4.56 4.23 3.83
Elevance Health Inc. 37.66 38.33 38.30 38.32 39.05 39.41 36.19 36.14 36.07 36.22 36.17 35.81 34.94 34.54 34.17 34.94 34.69
Intuitive Surgical Inc. 1.80 1.77 1.84 1.93 2.01 2.23 2.35 2.49 2.62 2.73 2.83 3.00 3.04 3.16 3.13 2.86 2.76
Medtronic PLC 5.28 5.54 5.57 5.57 5.61 5.66 5.82 5.88 5.85 6.05 6.13 6.12 5.77 5.56 5.64 5.72 5.99
UnitedHealth Group Inc. 37.44 38.37 38.90 35.98 32.10 32.18 31.60 31.35 31.81 33.07 32.33 32.16 31.81 31.77 30.94 30.76 29.64

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q4 2024 Calculation
Net fixed asset turnover = (Revenues from external customersQ4 2024 + Revenues from external customersQ3 2024 + Revenues from external customersQ2 2024 + Revenues from external customersQ1 2024) ÷ Property and equipment
= (65,372 + 63,609 + 60,202 + 56,965) ÷ 3,654 = 67.36

2 Click competitor name to see calculations.


Revenue Trends
The revenues from external customers exhibited an overall upward trajectory throughout the observed periods. Starting at approximately $38.1 billion in the first quarter of 2020, revenues experienced steady growth with occasional seasonal fluctuations. By the end of 2024, revenues reached about $65.4 billion, reflecting significant expansion and consistent increase in sales or service activities over the five-year timeframe.
Property and Equipment
The property and equipment asset base showed a general decline from about $4.3 billion in early 2020 to approximately $3.7 billion by the end of 2024. Although there were minor fluctuations, the trend indicates a gradual reduction or divestiture of physical assets over the period, possibly reflecting strategic asset management, disposition, or lower capital expenditures relative to depreciation.
Net Fixed Asset Turnover Ratio
The net fixed asset turnover ratio demonstrated a notable and steady increase from 37.85 in late 2020 to 67.36 by the end of 2024. This consistent improvement signals enhanced efficiency in utilizing fixed assets to generate revenues. Despite a declining asset base, the company was able to significantly increase the revenue produced per dollar of net fixed assets, implying operational improvements or shifts towards less capital-intensive revenue streams.
Overall Insights
The combination of increasing revenues coupled with decreasing fixed assets and rising turnover ratio suggests improved asset productivity and operational effectiveness. The company appears to be generating higher sales volumes or values while managing to reduce or optimize its investment in physical property and equipment. This pattern may indicate strategic shifts in business focus, technological upgrades, or efficiencies gained through better asset utilization.

Total Asset Turnover

Cigna Group, total asset turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Revenues from external customers 65,372 63,609 60,202 56,965 50,824 48,727 48,308 46,240 45,539 45,076 45,155 43,591 45,308 43,820 42,821 40,580 41,341 40,658 39,042 38,116
Total assets 155,881 157,639 155,446 153,119 152,761 149,645 150,054 147,976 143,932 144,209 152,630 152,610 154,889 154,251 154,207 152,081 155,451 160,044 159,628 154,711
Long-term Activity Ratio
Total asset turnover1 1.58 1.47 1.39 1.34 1.27 1.26 1.23 1.23 1.25 1.24 1.17 1.15 1.11 1.09 1.07 1.06 1.02
Benchmarks
Total Asset Turnover, Competitors2
Abbott Laboratories 0.52 0.55 0.56 0.56 0.55 0.55 0.55 0.56 0.59 0.62 0.61 0.60 0.57 0.57 0.55 0.51 0.48
Elevance Health Inc. 1.50 1.48 1.51 1.52 1.56 1.52 1.51 1.46 1.51 1.48 1.47 1.42 1.41 1.35 1.33 1.29 1.39
Intuitive Surgical Inc. 0.45 0.44 0.45 0.46 0.46 0.47 0.48 0.49 0.48 0.46 0.44 0.43 0.42 0.42 0.42 0.39 0.39
Medtronic PLC 0.36 0.36 0.35 0.35 0.34 0.33 0.33 0.35 0.35 0.35 0.35 0.34 0.32 0.29 0.29 0.30 0.32
UnitedHealth Group Inc. 1.32 1.30 1.33 1.32 1.34 1.26 1.23 1.18 1.31 1.29 1.32 1.33 1.34 1.30 1.29 1.27 1.30

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q4 2024 Calculation
Total asset turnover = (Revenues from external customersQ4 2024 + Revenues from external customersQ3 2024 + Revenues from external customersQ2 2024 + Revenues from external customersQ1 2024) ÷ Total assets
= (65,372 + 63,609 + 60,202 + 56,965) ÷ 155,881 = 1.58

2 Click competitor name to see calculations.


Revenue Trends
The revenues from external customers exhibit a general upward trend over the observed periods, increasing from approximately 38.1 billion US dollars in the first quarter of 2020 to about 65.4 billion US dollars by the last quarter of 2024. Notably, there are consistent quarter-to-quarter increases with occasional slight fluctuations, such as a minor dip in the first quarter of 2022 compared to the previous quarter. The most marked growth appears in the later periods, with revenue accelerating significantly from 56.9 billion US dollars in the first quarter of 2024 to 65.4 billion US dollars by year-end 2024.
Total Assets
Total assets have remained relatively stable over the analyzed timeframe, fluctuating within a range of approximately 143.9 billion to 160 billion US dollars. There is a slight downward shift from the early quarters of 2020 toward 2022, reaching a low point of around 143.9 billion US dollars at the close of 2022. Subsequently, the asset base gradually increases again, ending near 155.9 billion US dollars at the end of 2024. Overall, this indicates moderate asset management without substantial growth or contraction.
Total Asset Turnover
The total asset turnover ratio demonstrates a clear and steady upward trend, beginning near 1.02 in late 2020 and rising progressively to 1.58 by the final quarter of 2024. This ratio's increase suggests improving efficiency in the use of assets to generate revenues over time, reflecting better operational utilization and profitability potential relative to asset investments.
Summary of Insights
The combination of rising revenues and increasing asset turnover, alongside relatively stable total assets, indicates enhanced operational efficiency and revenue generation capacity without proportionate asset expansion. These patterns reflect positively on the company's ability to leverage existing assets to produce higher sales volumes. The periods of strongest revenue growth coincide with the highest asset turnover ratios, emphasizing effective asset utilization. The minor fluctuations in asset values do not detract from the overall trend of improving asset efficiency and top-line growth.

Equity Turnover

Cigna Group, equity turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Revenues from external customers 65,372 63,609 60,202 56,965 50,824 48,727 48,308 46,240 45,539 45,076 45,155 43,591 45,308 43,820 42,821 40,580 41,341 40,658 39,042 38,116
Shareholders’ equity 41,033 42,095 41,332 41,181 46,223 45,691 45,445 44,502 44,872 45,041 45,892 46,087 47,112 47,415 48,709 48,149 50,321 48,032 47,366 45,079
Long-term Activity Ratio
Equity turnover1 6.00 5.50 5.24 4.97 4.20 4.13 4.07 4.09 4.00 3.98 3.88 3.81 3.66 3.56 3.40 3.36 3.16
Benchmarks
Equity Turnover, Competitors2
Abbott Laboratories 0.88 1.04 1.04 1.04 1.04 1.07 1.08 1.12 1.19 1.26 1.25 1.26 1.20 1.23 1.19 1.11 1.06
Elevance Health Inc. 4.24 3.94 4.04 4.20 4.33 4.36 4.31 4.27 4.29 4.22 4.13 3.97 3.80 3.71 3.65 3.65 3.64
Intuitive Surgical Inc. 0.51 0.50 0.51 0.52 0.54 0.55 0.56 0.57 0.56 0.53 0.50 0.49 0.48 0.48 0.48 0.45 0.45
Medtronic PLC 0.64 0.62 0.62 0.62 0.61 0.60 0.59 0.59 0.60 0.60 0.61 0.61 0.59 0.55 0.56 0.56 0.57
UnitedHealth Group Inc. 4.26 4.12 4.27 4.33 4.14 4.22 4.19 4.10 4.14 4.19 4.18 4.06 3.98 3.95 3.92 3.94 3.90

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q4 2024 Calculation
Equity turnover = (Revenues from external customersQ4 2024 + Revenues from external customersQ3 2024 + Revenues from external customersQ2 2024 + Revenues from external customersQ1 2024) ÷ Shareholders’ equity
= (65,372 + 63,609 + 60,202 + 56,965) ÷ 41,033 = 6.00

2 Click competitor name to see calculations.


The financial data reveals several significant trends over the examined periods. Revenues from external customers exhibit a generally upward trajectory, with some fluctuations. Starting from approximately 38,116 million US dollars in March 2020, revenues increased steadily, reaching about 50,824 million by December 2023, and further accelerating to 65,372 million by December 2024. This growth indicates a consistent expansion in the company's market presence or sales volume over the four-year span.

Conversely, shareholders’ equity displays a declining trend over the same timeframe. Initially, equity was around 45,079 million in March 2020, peaking marginally in early 2021 but subsequently declining to 41,033 million by December 2024. The reduction in equity, especially from mid-2023 onwards, suggests either increased distributions, asset write-downs, or other factors reducing the net asset base.

The equity turnover ratio, which measures how efficiently the company generates revenues relative to shareholders’ equity, shows a marked and continuous increase from 3.16 in September 2020 to 6.0 by December 2024. This doubling of the ratio reflects improved utilization of equity to drive revenues despite the declining equity base. The combination of rising revenues and a shrinking equity base naturally results in higher turnover, indicating enhanced operational efficiency or leveraging.

In summary, the company has expanded its revenue base significantly over the period while its shareholders’ equity declined. The increasing equity turnover ratio underscores a trend of improving capital efficiency, which could be advantageous if sustainable. However, the falling equity raises questions about the long-term financial stability and warrants further analysis into the causes of equity reduction.